<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040582</identifier>
<setSpec>0213-2885</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">PSA and prostate cancer</dc:title>
<dc:description xml:lang="en">Summary: Prostatic specific antigen (PSA) is a very useful tumour marker as far as prostate cancer is concerned. We reviewed PSA and its application in clinical practie. Its biochemical and molecular features are described first. The asistance provided by this marker regarding screening, diagnosis and tumour staging of prostate cancer is then evaluated in depth. FinaUy, the interpretation that should be allocated to the PSA values following radical prostatectomy, radiation therapy, brachytherapy, cryotherapy, and also in the course of the follow-up of a metastatic and hormonoresistant pacient are analysed</dc:description>
<dc:creator>Segarra, J</dc:creator>
<dc:creator>Palou, J</dc:creator>
<dc:creator>Villavicencio, H</dc:creator>
<dc:creator>Huguet, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El antígeno prostático especifico (PSA) es un marcador tumoral de gran utilidad en el cáncer de    próstata. Realizamos una revisión sobre el PSA y su uso en la práctica clínica.    Inicialmente se describen sus características bioquímicas y moleculares. Posteriormente se    profundiza en la ayuda que supone disponer de este marcador en el screening, diagnóstico y    estadiaje tumoral del cáncer de próstata. Finalmente, se analiza que interpretación debe darse a    ws vawres del PSA después de prostatectomía radical,  radioterapia, braquiterapia, crioterapia    y durante el seguimiento de un paciente metastásico y en estado de hormonorresistencia</dc:description>
<dc:source>Actas Fund. Puigvert;24(1): 12-23, ene. 2005.</dc:source>
<dc:identifier>ibc-040582</dc:identifier>
<dc:title xml:lang="es">PSA y cáncer de próstata</dc:title>
<dc:subject>^d24373^s22073</dc:subject>
<dc:subject>^d24373^s22031</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d25123</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d9555^s22033</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d11914^s22057</dc:subject>
<dc:subject>^d11914^s22067</dc:subject>
<dc:subject>^d9555^s22067</dc:subject>
<dc:subject>^d11911^s22074</dc:subject>
<dc:subject>^d11911^s22045</dc:subject>
<dc:subject>^d11913^s22057</dc:subject>
<dc:subject>^d30596^s22073</dc:subject>
<dc:subject>^d11914^s22009</dc:subject>
<dc:subject>^d11913^s22009</dc:subject>
<dc:subject>^d30596^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>200501</dc:date>
</metadata>
</record>
</ibecs-document>
